• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Titan, Opiant partner to develop subcutaneous implant for opioid use disorder

October 5, 2017 By Sarah Faulkner

Titan PharmaceuticalsTitan Pharmaceuticals (NSDQ:TTNP) and Opiant Pharmaceuticals (NSDQ:OPNT) announced this week that the companies are partnering to develop a subcutaneous implant to deliver an opioid antagonist.

The pair said they plan to conduct a feasibility assessment of such an implant using Titan’s ProNeura sustained release technology. The goal of their collaboration is to devise a way to prevent opioid relapse and overdose in people with opioid use disorder, the companies said, by delivering therapeutic levels of an opioid antagonist for six months at a time.

As many as 91% of people with opioid use disorder in recovery will relapse, according to Titan, and at least 59% of people who relapse do so within their first week of sobriety.

“Currently, the only FDA-approved opioid antagonist for relapse prevention is a monthly depot injection of naltrexone,” Opiant CEO Dr. Roger Crystal said in prepared remarks.

“A product with a six-month duration would allow patients to be opioid-free for a longer period, providing a greater window for long-term recovery, and most critically, relapse and overdose prevention. This six-month duration would mean that patients only have to make one good decision to initiate therapy, which is important because the longer patients receive pharmacological treatment, the less likely they are to relapse and possibly overdose.”

“We are pleased to collaborate with Opiant on this important project to evaluate the addition of an opioid antagonist implant to the armamentarium of products to treat opioid use disorder,” Titan President and CEO Sunil Bhonsle added.

“Our knowledge from developing the FDA-approved Probuphine (buprenorphine) implant for the maintenance treatment of opioid addiction, coupled with the drug development expertise at both companies, should enable us to complete this evaluation relatively rapidly and, hopefully, with a successful result.”

Filed Under: Drug-Device Combinations, Featured, Implants, Pharmaceuticals, Wall Street Beat Tagged With: opiantpharmaceuticals, Titan Pharmaceuticals

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS